MAM
Vizeum launches consumer engagement service, ropes in Anand Kumar
MUMBAI: Aegis Media’s Vizeum India has appointed Anand Kumar as associate general manager – engagement planning for its newly launched active consumer engagement service.
Based in Mumbai, Kumar will report to Vizeum MD Indian sub-continent S Yesudas.
He moves in from Network18 Group where he was senior account group head- advertising and sales.
Yesudas said, “As the communication channel choices increase and the limited time at the consumers’ disposal further shrink, we believe we need to focus on engaging with consumers at different occasions and different state of mind based on the same strategic thread of the overall communication. Anand’s appointment is in line with this.
Passive advertising sells a particular product and makes the consumer walk to the point of sale.
However, there is a good chance that the consumer might walk out with a totally different brand because of some dynamics at the point of sale. On the other hand, had there been reinforcement of the message once again in the consumers’ mind as actively as possible just before the decision to pull out the wallet, chances are that the same brand would have been benefited. Both these scenarios call for different consumer engagements –the former talking ‘AT’ the consumer and the later, talking ‘WITH’ the consumer. Talking ‘WITH’ the consumer is all about actively engaging them at a different state of mind.”
Kumar said, “Vizeum India today is a strong and credible agency in just less than two and-a-half years. Their well articulated understanding of talking ‘At’ and ‘With’ consumers can further enhance thought leadership status. I look forward to working closely with the leadership team in Vizeum as they move to next level of aggressive growth and consolidation story.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
